Annual Estimates of Influenza Vaccine Effectiveness for Preventing Laboratory-Confirmed Influenza in the United States

Post Date

January 10th 2011

Application Due Date

March 1st 2011

On-time submission requires that electronic applications be error-free and made available to CDC for processing from eRA Commons on or before the deadline date. Applications must be submitted to and validated successfully by Grants.gov/eRA Commons no

Funding Opportunity Number

RFA-IP-11-003

CFDA Number(s)

93.185

Funding Instrument Type(s)

Cooperative Agreement

Funding Activity Categories

Health

Number of Awards

5

Eligibility Categories

Unrestricted

Funding

• Award Range:

  $0 - $785000

Grant Description

Influenza is an important cause of morbidity, mortality, and healthcare burden across all age groups. Because influenza viruses are constantly changing and vaccines are reformulated every year, annual estimates of the effectiveness of influenza vaccines in preventing influenza infection and its associated complications are needed in order to evaluate the protection provided by annual, nationwide vaccination programs. Estimating influenza vaccine effectiveness (VE) as soon as possible after the start of a seasonal influenza epidemic or pandemic and monitoring it over time will be essential in order to guide influenza vaccination and control policy. The populations to be studied will include those for whom CDC’s Advisory Committee on Immunization Practices recommends receipt of a licensed influenza vaccine. Influenza vaccination can prevent or reduce a number of outcomes, including laboratory-confirmed influenza virus infection, symptomatic illness given infection, severe illness and related complications due to influenza, the likelihood of transmitting the virus to others, or a combination of these. Thus, accurate estimation of vaccine effectiveness requires a multi-component approach, including accurate assessment of vaccination status, laboratory-confirmed disease outcomes, timing of illness and vaccination, and assessment of other factors that may affect vaccine use and immune response to vaccination. In addition, serological assessment of vaccine response and influenza antibody outcomes among vaccinated and unvaccinated individuals is also needed in order to understand vaccine response. Many additional factors can also affect the assessment of VE in observational studies such as the sensitivity and specificity of outcome measures, specimen collection methods, timing of vaccination, the setting for case and control recruitment, and the ratio of influenza illness to non-influenza respiratory illness. Moreover, a number of potential modifiers of vaccine response and vaccine effectiveness have been identified, including individual factors, environmental factors, and viral and infectious disease factors. Thus, applicants must describe plans to identify and control for a variety of potential confounders in each proposed analysis.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  Centers for Disease Control and Prevention

• Agency Contact:

  Centers for Disease Control and Prevention (CDC)
  Procurement and Grants Office (PGO)
  Technical Information and Managment Section (TIMS)
  Phone 770-488-2700

• Agency Mailing Address:

  General Email

• Agency Email Address:

  pgotim@cdc.gov

• Location:

  Centers for Disease Control and Prevention